fosfomycin and Labyrinth-Diseases

The protective effect of fosfomycin against aminoglycoside (dibekacin)-induced ototoxicity was studied in rats. Rats were injected with 100 or 50 mg/kg of dibekacin with or without 500 mg/kg of fosfomycin for 60 or 120 consecutive days. Inner ear damage appeared to be more reduced histopathologically in animals given both dibekacin and fosfomycin than in animals given dibekacin alone. Similarly, renal damage appeared to be reduced histopathologically and functionally by the combined administration of dibekacin and fosfomycin. The mechanism of reduced ototoxicity may be as follows: fosfomycin inhibits the accumulation of dibekacin in the kidney, and reduces its concentration in the kidney and serum. Consequently, the amounts of dibekacin reaching the inner ear are decreased, and ototoxicity is reduced.

Topics: Acetylglucosaminidase; Aminoglycosides; Animals; Anti-Bacterial Agents; Blood Urea Nitrogen; Cochlea; Dibekacin; Fosfomycin; Hair Cells, Auditory; Kidney; Kidney Diseases; Labyrinth Diseases; Perilymph; Proteinuria; Rats

The protective effect of fosfomycin against cisplatin-induced ototoxicity was studied in rats. Sixty-four Fischer rats were injected intravenously with daily doses of 1, 2, 5, and 10 mg/kg of cisplatin with or without 300 mg/kg of fosfomycin for a varying period from 1 to 10 days. The total dose of 10 mg/kg of cisplatin was given equally in all animals. Inner ear damage appeared to be more reduced histopathologically in animals given both cisplatin and fosfomycin than in animals given cisplatin alone. Similarly, renal damage appeared to be reduced histopathologically and functionally by the combined administration of cisplatin and fosfomycin.

Topics: Animals; Body Weight; Cisplatin; Cochlea; Fosfomycin; Hair Cells, Auditory; Kidney Diseases; Labyrinth Diseases; Male; Rats

Topics: Animals; Anti-Bacterial Agents; Dibekacin; Fosfomycin; Hair Cells, Auditory; Kanamycin; Kidney; Kidney Diseases; Labyrinth Diseases; Rats